

DAFTAR PUSTAKA

- Aarsland D, Brønneck K, Ehrt, et al.2007. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. *J Neurol Neurosurg Psychiatr* 78:36-42
- Abe K, Hikita T, Sakoda S.2005.Sleep disturbances in Japanese patients with Parkinson's disease-comparing with patients in the UK. *J Neurol Sci*;234:73-78
- Alatrisme-Booth V, Rodriguez-Violante M, Camacho-Ordonez A, Cervantes-Arriaga A.2015. Prevalence and correlates of sleep disorders in parkinson's disease: a polysomnographic study. *Arq Neuropsiquiatr* 73(3):241-245
- Albers JA, Chand P, Anch AM.2017. Multifactorial Sleep Disturbance in Parkinson's Disease. *Sleep Medicine*.S1389-9457
- Amara AW, Watts RL, Walker HC.2011. The effects of deep brain stimulation on sleep in Parkinson's disease. *Ther Adv Neurol Disord*;4:15-24
- Anthonius K, Rivani, Seily J, Denny JN.2018. Perbandingan Gangguan Tidur pada Lanjut Usia Dengan dan Tanpa Penyakit Parkinson. *Jurnal Sinaps*, Vol.I No.2:10-19
- Araujo VA, Lino-Neto J, de Sousa Ramalho F, Zanuncio JC, Serrao JE.2011. Ultrastructure and heteromorphism of spermatozoa in five species of bugs (Pentatomidae: Heteroptera). *Micron* 42, 560-567.
- Arnulf I, Ferraye M, Fraix V, Benabid AL, Chabardes S, Goetz L, et al.2010. Sleep induced by stimulation in the human pedunculopontine nucleus area. *Ann Neurol*;67:546-9
- Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, et al.2009. Cerebrospinal fluid-orexin level and sleep attack in four patients with Parkinson's disease. *Clin neurol Neurosurg*;111(4):341-344
- Baier G, Musyanovych A, Landfester K, Best A, Lorenz S, Mailander V.2011. DNA amplification via polymerase chain reaction inside miniemulsion droplets with subsequent poly (n-butylcyanoacrylate) shell formation and delivery of polymeric capsules into mammalian cells. *Macromolecular Bioscience* 11,1099-1109.
- Barbeau A.1984. Etiology of Parkinson's disease: a research strategy. *Can. J. Neurol. Sci*;11:24-28
- Baumann CR, Bassetti CL.2005. Hypocretins (orexins) and sleep-wake disorders. *Lancet Neurol*;4:673-82
- Baumann C, Ferini-Strambi I, Waldvogel D, Werh E, Bassetti CL.2005. Parkinsonism with excessive daytime sleepiness- a narcolepsy-like disorder? *J Neurol*;252: 139-45

Berridge CW, Schmeichel BE, Espana RA.2012. Noradrenergik modulation of wakefulness/arousal. *Sleep Med Rev.*16(2);p 187-97

Billiard M.2007. Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the International Classification of Sleep Disorders, 2nd edition. *Sleep Med Rev.*

Brodsky M, Godbold J, Roth T, Olanow C.2003. Sleepiness in Parkinson's disease: A controlled study. *Movement Disorders*,18(6).668-672.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E.2003. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*;24:197-211

Carlson NR. Neurotransmitters and Neuromodulators.2014. Dalam: *Physiology of Behaviour*, Edisi ke-8. Massachusetts, Pearson:112-128

Carney P.2005. *Clinical Sleep Disorder*. Lippincot Williams & Wilkins.Philadelphia.p;21-58

Chaudhuri K, Pal S, Di Marco A, et al.2002.The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. *J. Neurol Neurosurg Psychiatry*:73:629-635

Chen Q, Lecea L, Hu Z, Gao D.2014. The Hypocretin/ Orexin System: An Increasingly Important Role in Neuropsychiatry. *Wiley Periodicals, Inc. Medicinal Research Reviews*,00, No.0,1-46

Chen Q, Lesnefsky EJ.2011. Blockade of electron transport during ischemia pre-serves bcl-2 and inhibits opening of the mitochondrial permeability transition pore. *FEBS Letters* 585, 921-926.

Cheryl HW.1999. *Diagnosis and Management Parkinsons Disease*. Profesional Communication Inc.

Chokroverty S.2009. *Sleep Disorders Medicine*. Saunders Elsevier. Philadelphia.USA.p;96-111

Chow, M. and Cao, M. 2016. The hypocretin/orexin system in sleep disorders: Preclinical insights and clinical progress. *Nature and Science of Sleep*, 8, pp. 81-86.

Christopher GG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. 2004. *Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: Status and Recommendations*. *Movement Disorders* Vol. 19, No. 9 ; 1020-1028

Collins LM, Toulouse A, Connor TJ, Nolan YM.2012. Contribution of central and systemic inflammation to the pathophysiologi of Parkinson's disease. *Neuropharmacology*, 62, hal.2154-2168

Das BB, Dexheimer TS, Maddali K, Pommier Y.2010. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. *Proceedings of the National Academy of Sciences of the United States of America* 107, 19790-19795.

Dhawan V, Healy DG, Pal S, Chaudhuri KR.2006. Sleep-related problems of Parkinson's disease. *Age and Ageing*;35:220-228

Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al.2009. Neuropathological assessment of Parkinson's disease:refining the diagnostic criteria. *Lancet Neurology* 8, 1150-1157.

Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J.2005. Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients. *Sleep Med*;6:313-8

Dodel R.2004. Dementia In Parkinson's Disease. Orphanet Encyclopedia.p1-5, diunduh dari <http://www.orpha.net/data/patho/GB/uk-PDD.pdf>

Durrenberger, PF et al.2012. Inflammatory pathways in Parkinson's disease; A BNE microarray study. *Parkinson's Disease*.

Drouot X, Moutereau S, Nguyen JP, Lefaucher JP, Creange A, Remy P et al.2003.Low levels of ventricular CSF orexin/ hypocretin in advanced PD. *Neurology* 61(4):540-543

Ertracht O, Liani E, Bachner-Hinenzon N, Bar-Am O, Frolov L, Ovcharenko E, et al.2011. The cardioprotective efficacy of TVP1022 in rat model of ischaemia/reperfusion. *British Journal of Pharmacology* 163, 755-769.

Factor A, Weiner J. 2008. Parkinson's disease: Diagnosis and clinical management. Second edition. Cardinal feature of early Parkinson's disease;47-49.

Fritsch T, Smyth KA, Wallendal MS, Hyde T, Leo G, Geldmacher DS.2012. Parkinson Disease: Research Update and Clinical Management. *Southern Medical Journal*,105(12), p.650-656

Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG et al.2007. Hypocretin (orexin) loss in Parkinson's disease. *Brain* 130, 1577-1585.

Ganjavi H, Shapiro CM.2007. Hipocretin/ Orexyn : A Molecular Link Between Sleep, Energy Regulation and Pleasure. *J. Neuropsychiatry Clin Neurosci* 19:4;413-19

Geigenberger P.2011. Regulation of starch biosynthesis in response to a fluctuating environment. *Plant Physiology* 155, 1566-1577

Gerashchenko D, Murillo-Rodriguez E, Lin I, et al.2003. Relationship between CSF hypocretin levels and hypocretin neuronal loss. *Exp Neurol*;184:1010-6

Gofir A, Astuti. 2018. Pemeriksaan Gangguan Tidur. Dalam buku Panduan Tatalaksana Gangguan Tidur.Ed 2. Editor: Islamiah WR. Jakarta:PERDOSSI. Sagung Seto;hal 41-62

Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S et al.1999. Orexin a activates locus coeruleus cell firing and increases arousal in the rat. *Proc. Nat. Acad. Sci. USA*.96, 10911-10916.

Happe S, Baier PC, Helmschmied K, Meller J, Tatsch K, Paulus W. 2007. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. *J Neurol*.254:1037-1043

Hauser RA, Lyons KE.2003. Parkinson Disease Questions and Answer. USA, Merit Publishing International: 49-59.

Hirsch EC.1999. Mechanism and consequences of nerve cell death in Parkinson's disease. In: Przuntek, h dan Muller, T. (eds.). Diagnosis and treatment of Parkinson's disease-state of the art. Wien: Springer-Verlag, hal.127-137.

Hirsch EC, Jenner P, Przedborski S. 2013. Pathogenesis of Parkinson's Disease. *Movement Disorders* 28: 24-30

Husni A.2002. Penyakit Parkinson, patofisiologi, diagnosis dan wacana terapi. Disampaikan pada Temu Ilmiah Nasional I dan konferensi kerja III PERGEMI. Semarang.

Imperatore R, Palomba L and Cristino L.2017. Role of Orexin-a in hypertension and obesity. *Curr. Hypertens. Rep.*19:34

Jankovic J.2008. Parkinson's disease; clinical features and diagnosis. *J. Neurol.. Neurosurg.Psychiatr.*79,368-376.

Jellinger K.2014. Neuropathology of Parkinson's Disease. Inflammation in Parkinson's Disease: Scientific and Clinical Aspects;36-40

Joesoef AA.2001. Patofisiologi dan manajemen penyakit Parkinson. Dalam: Pendidikan Kedokteran Berkelanjutan V. FK Unair:27-53

Johns MW, 1991. A New Method For Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. *Sleep*; 14:540-5

Johns MW, 1997. The Epworth Sleepiness Scale. diakses tanggal 28 Juli 2021 <https://epworthsleepinessscale.com/about-the-ess/>

Kao JP, Li G, Auston DA.2010. Practical aspect of measuring intracellular calcium signals with fluorescent indicators. *Methods in cell biology* 99,113-152.

Knie B, Mitra M, Logishetty K, Chaudhuri K.2011. Excessive daytime sleepiness in patients with Parkinson's disease. *CNS drugs*,25(3).203-212.

Koutoudis, Ted K.2010.Parkinson's Disease, diunduh dari http://emedicinehealth.com/parkinson_disease/article_em.htm

Kumar S, Bhatia M, Behari M.2002. Sleep Disorders in Parkinson's Disease. *Mov Disord*, 17, 775-781

Kryger M.2005.Principles of Sleep Medicine. Elsevier Saunders. Philadelphia. USA.p;9-12

Lailiyya N, 2018. Anatomi dan Fisiologi Tidur. Dalam buku Panduan Tatalaksana Gangguan Tidur.Ed 2. Editor: Islamiah WR. Jakarta:PERDOSSI. Sagung Seto;hal 1-28

Louter M, Aarden WCCA, Lion J, Bloem BR, Overeem S.2012. Recognition and diagnosis of sleep disorders in Parkinson's disease. *J Neurol*.259:2031-2040

Manubulu W, Syamsudin T, Lailiyya N.2014. Karakteristik Gangguan Tidur Pada Penyakit Parkinson Berdasarkan Parkinson Disease Sleep Scale. *Neurona Vol.31 No.4*

Muller FL, Liu Y, Van Remmen H.2004. Complex III release superoxide to both sides of inner mitochondrial membrane. *Journal of Biological Chemistry* 279, 49064-49073.

Muzerengu S, Contrafatto D, Chaudhuri K. 2007. Non-motor symptoms: Identification and management. *Parkinsonism and Related Disorders* 13 : 450–456.

Ohtsuka C et al.2013. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelamin-sensitive MR imaging. *Neurosci Lett*,541;p.93-8.

Okun MS, Watts RL.2002.Depression associated with Parkinson's Disease. *Neurology*;58:63-70

Ondo WG, 2014. Sleep/wake problems in Parkinson's disease: pathophysiology and clinicopathologic correlations. *Neurology and Preclinical Neurological Studies-Review article*.

Pahwa P, karunanayake CP, Hagel L, Gjevre JA, Rennie D, Lawson JA, et al.2012. Prevalence of high Epworth Sleepiness Scale Score in a rural population. *Can Respir J*;19(2):10-4

Paus S, Brecht H, Koster J, Seeger G, Klockgether T, Wullner U.2003. Sleep attacks, daytime sleepiness and dopamine agonists in Parkinson's disease. *Movement Disorders*,18(6).659-667.

PERDOSSI, 2013.Penyakit Parkinson dan Gangguan Gerak Lainnya. Buku Panduan Tatalaksana.

Poewe W, Tanner C, Halliday G, Brundin P, Volkman J, Schrag A, Lang A.2017. Parkinson disease. *Nature Reviews Disease Primers*, 3:17013.

Posner J.2007. Plum and Posner. *Diagnosis of Stupor and Coma*. 4th Edition. Oxford University Press. New York.p;11-25

Qiu MH et al.2010.Basal ganglia control of sleep-wake behavior and cortical activation. *Eur J Neurosci*.31(3):p 499-507

Reeve A, Simcox E, Turnbull D.2014. Ageing and Parkinson's disease: Why is advancing age the biggest risk factors?. *Ageing Research Reviews*, 14:19-30

Remy P, Doder M, Lees A, Turjanski N, Brooks D.2005. Depression in Parkinson's disease: loss of dopamine and noradrenalin innervation in the limbic system. *Brain*. 128,1314-1322

Rewar.2015. A Systemic review on Parkinson's Disease. Indian Journal of Research in Pharmacy and Biotechnology. p.176-185

Riederer P, Gerlach M, Foley P.2002. Neurotransmitters and Pharmacology of the Basal Ganglia. Dalam: Parkinson's Disease and Movement Disorders, Edisi ke-4. Philadelphia, Lippincott Williams & Wilkins:23-35

Ropper A.2005. Adam and Victor's Principles of Neurology 9th Edition. Mc Graw-Hill. USA.p;333-337

Rye D.2006. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Current Neurology and Neuroscience Reports,6(2).169-176.

Rye DB. 2004. The two faces of Eve; dopamin's modulation of wakefulness and sleep. Neurology;63:280-3

Rye DB, Bliwise DL, Dihenia B, Gurecki P.2000. Daytime sleepiness in Parkinson's disease. J Sleep Res;9:63-9

Sai Y, Zou Z, Peng K, Dong Z.2012. The Parkinson's disease-related genes act in mitochondrial homeostasis. Neuroscience and Biobehavioral Reviews.36:2034-2043

Sakurai T, Mieda M, Tsujino N.2010. The orexin system : roles in sleep/ wake regulation. Ann. N. Y. Sci.1200;149-161

Saper CB, Chou TC, Scammell TE.2001.The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci;24;726-31

Scaravilli T, Gasparoli E, Rinaldi F, Polesello G, & Bracco F.2003. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci, 24,209-210

Sharma J, Nelluru G, Wilson MA, Johnston MV, Hossain MA.2011.Sex-specific activation of cell death signaling pathways in cerebellar granule neurons exposed to oxygen glucose deprivation followed by reoxygenation. ASN Neuro,3.

Stickgold R.2009. The Neuroscience of Sleep. Elsevier. London.p;12-16

Suzuki K, Miyamoto K, Miyamoto M, Numao A, Sakuta H, Fujita H et al, 2018. Sleep Disturbances in Patients with Parkinson's Disease. Chapter from the book: A Synopsis of Parkinson's Disease. Downloaded from: <http://www.intechopen.com/books/a-synopsis-of-parkinson's-disease>.

Suzuki K, Miyamoto M, Miyamoto T, Iwanami M, Hirata K.2011. Sleep Disturbances Associated with Parkinson's Disease. SAGE-Hindawi Access to Research Parkinson's Disease;article ID 219056, 10 pages

Suzuki K, Okuma Y, Hattori N, Kamei S, Yoshii F, Utsumi H et al.2007. Characteristics of Sleep Disturbances in Japanese Patients with Parkinson's Disease. A Study Using Parkinson's Disease Sleep Scale. Movement Disorder Society, 22:9:1245-1251

Syamsudin T, Dewanto G, Subagya, Tumeweh R, Nasution D, Husni A, et al.2013. Penyakit Parkinson dan Gangguan Gerak Lainnya. Kelompok Studi Movement Disorders Perdossi Jakarta.

Tandberg E, Larsen JP, & Karlsen K.1998. A community-based study of sleep disorders in patients with Parkinson's disease. *Mov Disord*, 13, 895-899.

Tansey MG, Goldberg MS.2010. Neuroinflammation in Parkinson's disease:its role in neuronal death and implications for therapeutic intervention. *Neurobiol Dis.*,37(3), hal.510-518.

Thannickal TC, Lai YY, Siegel JM.2007. Hypocretin (orexin) cell loss in Parkinson's disease. *Brain*;130(Pt 6):1586-1595)

Thannickal TC, Moore RY, Nienhuis R, et al.2000. Reduced number of hypocretin neurons in human narcolepsy. *Neuron*;27:469-74

Thannickal TC, Siegel JM, Moore RY.2003. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. *Brain Pathol*;13:340-5

Trotti LM, Rye DB.2009. Neurobiology of Sleep: the role of dopamine in Parkinson's disease. In: Chaudhuri KR, Tolosa E, Schapira A, Poewe W, editors. *Non-motor symptoms in Parkinson's disease*. Oxford University Press;p.165-76

Vaughn BV, D'Cruz OF, Cardinal manifestations of sleep Disorders. Dalam kryger M, et al. *Principles and practices of sleep medicine 4th edition*. Elsevier Saunders, Philadelphia 2005:594-601

Vendette M, Gagnon JF, Decary A, Massicotte-Marquez J, Postuma RB, Doyon J et al.2007.REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. *Neurology*;69(19):1843-1849.

Verbaan D, van Rooden S, Visser M, Marinus J, van Hilten J.2008. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. *Movement Disorders*,23(1).35-41.

Vetrivelan R et al.2010. Role of Basal Ganglia in sleep-wake regulation: neural circuitry and clinical significance. *Front Neuroanat*.4:p 145

Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M et al.2012. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? *J. Sleep Res*.21, 710-717.

Willis A, Evanoff B, Lian M, Criswell S, and Racette B. 2010. Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. *Neuroepidemiology*, 34(3):143-151.

Ylikoski A, Martikainen K, Sieminski M, Partinen M.2017. Sleeping difficulties and health-related quality of life in Parkinson's disease. *Acta Neurologica Scandinavia*, 135(4),459-468.

Yousaf T, Pagano G, Niccolini F, Politis M.2018. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. *J Neurol Sci.*387:220-227.

